Kiudro

Mesalazine, the active ingredient in Kiudro, is a aminosalicylate presented as a rectal formulation for rectal use. It treats ulcerative colitis and mild to moderate inflammatory bowel disease of the distal colon. GNH USA supplies Kiudro as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kiudro, an aminosalicylate, is used to manage inflammatory conditions of the colon. - Ulcerative colitis: induction and maintenance of remission in patients with disease affecting the colon. - Distal ulcerative colitis: reduces inflammation in the distal segment of the colon. - Mild to moderate inflammatory bowel disease of the distal colon: helps achieve symptom control and mucosal healing.

Common Side Effects: - Rectal irritation or burning sensation. - Abdominal cramps or discomfort. - Diarrhea or loose stools. - Nausea or mild headache.

Serious or Rare Side Effects: - Severe allergic reaction, including anaphylaxis. - Blood dyscrasias such as neutropenia or agranulocytosis. - Renal impairment or worsening kidney function.

Before initiating therapy, evaluate disease severity and renal function. - Assess disease severity: confirm that rectal therapy is appropriate for the extent of colitis. - Monitor renal function: periodic testing is recommended, especially in patients with pre‑existing kidney disease. - Monitor blood counts: watch for signs of leukopenia or anemia. - Avoid in patients with known hypersensitivity to salicylates or aminosalicylates. - Use with caution during pregnancy or breastfeeding: benefits must outweigh potential risks. - Store at room temperature: keep in the original pack, protect from moisture and light.

Mesalazine may interact with several drug classes. Major Interactions (Avoid): - Concurrent systemic NSAIDs: increased risk of gastrointestinal toxicity. - Anticoagulants (e.g., warfarin): heightened bleeding tendency. - Sulfasalazine: potential for additive hypersensitivity reactions.

Moderate Interactions (Monitor Closely): - Azathioprine: may enhance myelosuppression. - Methotrexate: possible increase in hepatic toxicity. - Oral contraceptives: may reduce contraceptive efficacy.